Drs. Regillo, Dunbar, Sheth, and Theis will discuss the unmet needs in diabetic eye disease, emerging treatments that may address those needs, and patient selection and education.
This activity is supported by an unrestricted educational grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 124516, is accredited by COPE for continuing education for optometrists. This course is approved for 1.5 hours CE.
Course #: 80024-TD
Activity #: 124516
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Carl D. Regillo, MD, FACS
Chief, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Retina Surgeon
Mid Atlantic Retina
Philadelphia, PA
Mark T. Dunbar, OD, FAAO
Director of Optometric Services
Bascom Palmer Eye Institute
University of Miami School of Medicine
Miami, FL
Veeral S. Sheth, MD, MBA, FASRS, FACS
Director of Clinical Research
University Retina and Macula Associates
Board Certified Ophthalmologist and Retinal Surgeon
Clinical Assistant Professor
University of Illinois at Chicago
Chicago, IL
Jacqueline Theis, OD, FAAO
Virginia Neuro-Optometry
Richmond, VA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Carl D. Regillo, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Adverum Biotechnologies, Allergan, Annexon, Apellis, Clearside, EyePoint Pharmaceuticals, Genentech, Graybug, Iveric Bio, Kodiac, NGM, Novartis, and Regenxbio. Grant/Research Support: Adverum Biotechnologies, Allergan, Annexon, Apellis, Genentech, Graybug, Iveric Bio, Kodiac, NGM, Novartis, Opthea, Regeneron, and Regenxbio.
Mark T. Dunbar, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Allergan, Carl Zeiss Meditec, Genentech, Reed Exibitions, Regeneron, and Tarsus. Consultant: Allergan, Avellino, Carl Zeiss Meditec, Genentech, Iveric Bio, Orasis Pharmaceuticals, Regeneron, and Visus. Speaker's Bureau: Allergan, Carl Zeiss Meditec, and Regeneron.
Veeral S. Sheth, MD, MBA, FASRS, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Apellis, EyePoint Pharmaceuticals, Genentech, Graybug, Iveric Bio, Novartis, and Regeneron. Grant/Research Support: 4D Molecular Therapeutics, Alimera Sciences, Allergan, Ashvattha Therapeutics, Chengdu Kanghong Biotechnology, EyePoint Pharmaceuticals, Genentech, Gyroscope, Ionis, Iveric Bio, NGM Biopharmaceuticals, Novartis, Opthea, Outlook, Oxurion, Recens Medical, Regeneron, Regenxbio, Roche, SalutarisMD, SamChungDang, and Santen. Speaker’s Bureau: Alimera Sciences, Apellis, and Genentech.
Jacqueline Theis, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant/Advisory Board: C. Light Technologies and Horizon Therapeutics. Speaker's Bureau: Oculus. Stock/Shareholder: Vision Science Labs.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 creditDeepak Sambhara, MD
Janis T. Eells, Ph.D.
David Boyer, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
